{"disease":{"id":"frown-lines","name":"frown lines"},"drugs":{"marketed":[{"drug_id":"botulinum-toxin-type-a","indication_name":"Rhytidectomy of glabellar frown lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":51,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03004248","title":"Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2691,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT02677298","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":784,"lead_sponsor_name":"Croma-Pharma GmbH","has_results":true},{"nct_id":"NCT06585696","title":"A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":554,"lead_sponsor_name":"Cutia Therapeutics（Wuxi）Co.,Ltd","has_results":false},{"nct_id":"NCT04247074","title":"Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":413,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT03985982","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":410,"lead_sponsor_name":"Croma-Pharma GmbH","has_results":true},{"nct_id":"NCT03736928","title":"Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT04622254","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Merz North America, Inc.","has_results":true},{"nct_id":"NCT04594213","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":362,"lead_sponsor_name":"Merz North America, Inc.","has_results":true},{"nct_id":"NCT05059587","title":"Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Medytox Korea","has_results":false},{"nct_id":"NCT03014635","title":"Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":306,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03014622","title":"Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":303,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03960957","title":"Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":301,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT05623410","title":"Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"ATGC Co., Ltd.","has_results":false},{"nct_id":"NCT03289169","title":"Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT04249583","title":"Treatment of Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT04830345","title":"Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"EuBiologics Co.,Ltd","has_results":false},{"nct_id":"NCT05364580","title":"The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Protox Inc.","has_results":false},{"nct_id":"NCT03440671","title":"The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":260,"lead_sponsor_name":"Huons Co., Ltd.","has_results":false},{"nct_id":"NCT05321979","title":"Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"Medytox Korea","has_results":false},{"nct_id":"NCT02677805","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Croma-Pharma GmbH","has_results":true},{"nct_id":"NCT03806933","title":"Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":241,"lead_sponsor_name":"Merz Aesthetics GmbH","has_results":true},{"nct_id":"NCT04763265","title":"Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Croma-Pharma GmbH","has_results":true},{"nct_id":"NCT04143815","title":"Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT04281745","title":"Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT01391299","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines","phase":"NA","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06124794","title":"The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"Protox Inc.","has_results":false},{"nct_id":"NCT05320393","title":"Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"Evolus, Inc.","has_results":true},{"nct_id":"NCT05277337","title":"Study Comparing Treatment With Alluzience vs Reconstituted Toxin","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT06946160","title":"A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Espad Pharmed","has_results":false},{"nct_id":"NCT03837561","title":"The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT05146999","title":"Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT01485601","title":"Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Medy-Tox","has_results":true},{"nct_id":"NCT03687736","title":"Subject Satisfaction With AbobutulinumtoxinA Treatment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT05565950","title":"AI-09 In Subjects With Glabellar Lines, GL-101","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Eirion Therapeutics Inc.","has_results":false},{"nct_id":"NCT03786770","title":"Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04996810","title":"The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Protox Inc.","has_results":false},{"nct_id":"NCT04281095","title":"A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"ATGC Co., Ltd.","has_results":false},{"nct_id":"NCT05217355","title":"A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Medytox Korea","has_results":false},{"nct_id":"NCT05083286","title":"Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Clinical Testing of Beverly Hills","has_results":false},{"nct_id":"NCT05129319","title":"Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Clinical Testing of Beverly Hills","has_results":false},{"nct_id":"NCT06411002","title":"Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05148000","title":"Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Galderma R&D","has_results":false},{"nct_id":"NCT05517538","title":"Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Mohamed Hayder Oleish Salih","has_results":false},{"nct_id":"NCT05222607","title":"Longitudinal Evaluation and Real-world Evidence of NT201","phase":"","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Merz North America, Inc.","has_results":false}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}